This week, ten customers, including one new, placed sales orders totaling KEUR 66 (KESEK 763) with Eevia. These included KEUR 11 from a French partner and KEUR 8 from another European customer for Feno-Myrtillus 25. The European customer, using the bilberry extract in animal feed, represents a promising high-volume opportunity. A Finnish customer also ordered KEUR 10 of bilberry products, and Eevia received an order for a bilberry product from Select Ingredients for a US-based organic brand.
 

Another Finnish customer ordered KEUR 7 of Fenoprolic 70 Organic, while a German customer placed an KEUR 10 order for the same product through Eevia’s German distributor Breko. Additionally, there were orders for Feno-Chaga Organic in the US via Eevia’s distributor NutriOriginal, and a small first order for Feno-Ceraus 5 Organic (tart cherry extract) in the US. We also gained a new Latvian customer with a KEUR 3 order for bilberry extract.

The orders, mainly through distributors, support end customers building high-quality natural brands. Except for Feno-Ceraus 5, all products are in stock, allowing immediate delivery without the need for raw material purchases, which benefits cash flow. Eevia has raw material for Feno-Ceraus 5 and can produce it quickly. These are repeat orders, and further orders from these customers are expected.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com                      

Telephone: +358 400 22 5967                         

Information about Eevia Health Plc

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials, with a focus on gut and related health areas, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

As a pioneering company Eevia is developing biomaterials that may have dramatic impact on human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.